The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the biotech CureVac.

Bird flu has emerged as a critical public health concern in California, with Governor Gavin Newsom declaring a state of ...

influenza, malaria, and others. In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily.

GSK’s influenza vaccine, Fluarix Quadrivalent, has been approved by the US FDA for the immunisation of adults and children aged three years and older to help prevent disease caused by seasonal ...

Novartis and GSK are currently furthest advanced in developing these technologies for influenza. Both companies have already received European approval to make products using their oil-in-water ...

GSK. The vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, is for use in people 18 years of age and older who are at increased risk of exposure to the H5N1 influenza virus.

GlaxoSmithKline will supply 8 million doses of its flu vaccine, Fluarix. This dosage is twice the amount GSK shipped to US last year. GlaxoSmithKline will supply 8 million doses of its flu vaccine ...

The vaccine involved in the latest government deal, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce a flu vaccine ...

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and ...